Search Results

Home → Flash News → Class B GPCR drugs are reshaping treatment for migraine, diabetes, and obesity- but did you know ligand bias plays a key role in their success? This new review explores how tweaking peptide drugs can boost efficacy, reduce side effects, and unlock next-gen therapies. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://www.ecosystem.drgpcr.com/reviews/where-are-we-now%3F-biased-signalling-of-class-b-g-protein-coupled-receptor-targeted-therapeutics #gpcr#drgpcr Published on June 2, 2025 Category GPCR Weekly News Class B GPCR drugs are reshaping treatment for migraine, diabetes, and obesity- but did you know ligand bias plays a key role in their success? This new review explores how tweaking peptide drugs can boost efficacy, reduce side effects, and unlock next-gen therapies. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https://www.ecosystem.drgpcr.com/reviews/where-are-we-now%3F-biased-signalling-of-class-b-g-protein-coupled-receptor-targeted-therapeutics #gpcr#drgpcr Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Dr. Jennifer Pluznick About this episode Dr. Pluznick discovered that olfactory receptors in mice are also expressed in their kidneys and blood vessels. Her research is focused on the role of chemosensory GPCRs in regulating renal and cardiovascular function, and identifying renal/cardiovascular olfactory receptor ligands, and relating them to whole-animal physiology. This work contributes to a better understanding of how the kidney helps maintain homeostasis in humans. Jennifer is currently an assistant professor of physiology at the Johns Hopkins School of Medicine. She received her undergraduate degree in biology from Truman State University and earned her Ph.D. in renal physiology from the University of Nebraska Medical Center. She then spent five years training as a postdoctoral fellow in the laboratory of Michael Caplan at Yale University, where she studied both renal physiology and sensory biology systems and focused on olfaction. Dr. Jennifer Pluznick on the web John Hopkins Pluznick Lab Pubmed Ted Talk Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic Drugs” closes March 18th! If you’re working on GPCR drug discovery, you know that finding a promising candidate is just the start. A drug must also: ✅ Be absorbed into the body ✅ Reach the right target ✅ Stay long enough to be effective ✅ Cause no harm 📢 Spots are limited—register by March 18th! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery Published on March 10, 2025 Category Dr. GPCR Courses ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic Drugs” closes March 18th! If you’re working on GPCR drug discovery , you know that finding a promising candidate is just the start. A drug must also:✅ Be absorbed into the body✅ Reach the right target✅ Stay long enough to be effective✅ Cause no harm 📢 Spots are limited—register by March 18th! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Sri Kosuri About Dr. Sri Kosuri Sri is a biologist that has helped build technologies, labs, and companies in synthetic biology, functional genomics, and bioinformatics over the last 20 years. He is passionate about developing more rational ways to understand and engineer biology. Sri is a co-founder at Octant and an Associate Professor at UCLA in the Chemistry and Biochemistry Department. His lab has worked on building large-scale ways of empirically exploring questions in protein biochemistry, human genetic variation, gene regulation, chemical biology, synthetic biology, and functional genomics. Sri previously worked at the Wyss Institute and Harvard, where he built numerous technologies in gene synthesis, DNA information storage, gene editing, and large-scale multiplexed assays. He helped build Gen9, a gene synthesis company, as a member of the SAB and was the first employee of Joule Unlimited, an engineered algal biofuel company. He is a Searle Scholar (2015), NIH New Innovator (2014), and received his ScD in Biological Engineering at MIT and BS in Bioengineering at UC Berkeley. Sri is originally from New Jersey, Philadelphia, and Kansas and was born in North Carolina. He enjoys eating, getting outdoors, and traveling with his wife and two children. Dr. Sri Kosuri on the web Octant Kosuri Lab Twitter LinkedIn Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → Started in medicinal chemistry. Got hooked on ligand design. Dr. Maria Majellaro didn’t plan to run a biotech company. A thesis project, a mentor’s advice, and a leap during the pandemic changed everything. Now she’s leading Celtarys, building custom fluorescent probes, and partnering with Dr. GPCR to support assay development worldwide. Meet Celtarys and learn more about its leading work on ligand-linker-fluorophore chemistry 🚀 ✳️ Listen now: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-168-with-dr.-maria-majellaro-from-celtarys #GPCRcommunity #DrGPCR #FluorescentLigands #GPCRdrugDiscovery #ScientificLeadership #BiotechInnovation Published on June 19, 2025 Category Dr. GPCR Podcast Started in medicinal chemistry. Got hooked on ligand design. Dr. Maria Majellaro didn’t plan to run a biotech company. A thesis project, a mentor’s advice, and a leap during the pandemic changed everything. Now she’s leading Celtarys, building custom fluorescent probes, and partnering with Dr. GPCR to support assay development worldwide. Meet Celtarys and learn more about its leading work on ligand-linker-fluorophore chemistry 🚀 ✳️ Listen now: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-168-with-dr.-maria-majellaro-from-celtarys #GPCRcommunity #DrGPCR #FluorescentLigands #GPCRdrugDiscovery #ScientificLeadership #BiotechInnovation Previous Next Recent Articles Early Stage Biotech Hiring: What Really Holds a Team Together When the Science Starts to Drift 👉 In early-stage biotech , uncertainty is not an exception. It is the environment. The science evolves, assumptions break, and timelines shift quietly rather than dramatically. Most founders are prepared for this on a technical level. What they are less prepared for is how much this uncertainty tests the team. Early hiring decisions are usually made around skills, experience, and domain expertise. That feels logical. 👉 Complex biology seems to demand strong credentials. Bu Attila Foris 5 days ago The One Reason Why Biotech Startups Fail More Often Than They Should Biotech startups rarely fail all at once. They fail while everyone is still working hard. Experiments continue. Meetings happen. Progress is reported. Yet alignment fades and decisions lose clarity. This is not a motivation problem. It is structural. When complexity grows faster than strategy, biotech companies drift. Survival depends less on science and more on whether clarity scales with complexity. Attila Foris Jan 7 Why Biotech Fundraising Fails Due to Intellectual Property Gaps 👉 Why has intellectual property become a first-order fundraising signal? Biotech fundraising has undergone a subtle yet significant shift. Capital still exists, but investors are making decisions earlier and filtering more carefully . As a result, intellectual property is no longer something that comes up late in the process. 👉 It has become an early signal of whether a biotech company is fundable at all. This shift does not mean founders need more patents or heavier legal Attila Foris Dec 31, 2025 The Hidden Operating Cadence That’s Actually Driving Your Biotech Founders love the idea that a new year, or a new quarter, will reset the company. But here’s the uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design. And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus. Most CEOs think they’re steering the strategy. 👉 In reality, their operating cadence is steering them. And until you see it, you can’t change it. Operating cadence Attila Foris Dec 24, 2025 GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026 As scientists, we know curves don’t equal clarity. As 2025 comes to a close, this final edition of Weekly News focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape SAR, lead selection, and development timelines long before anyone notices. The goal isn’t more data. It’s cleaner interpretation. And that’s exactly what carries strong discovery programs into 2026. Dr. GPCR News Dec 18, 2025

<< Back to podcast list Strategic Partner(s) Julia Gardner About Julia Gardner Julia is a senior undergraduate student at Duke University, where she studies chemistry and Chinese. Julia has been working as a researcher in Duke's Rajagopal Lab since her first year as an undergraduate. In the Rajagopal Lab, Julia studies the mechanisms of 'biased signaling' at GPCRs, with a specific focus on the chemokine receptor CXCR3. She recently led a project that demonstrated the GPCR kinases (GRKs) can translocate to endosomes, and that the subcellular localization of the GRKs affects a GPCR's biased signaling profile. Last summer, Julia worked at as the first-ever summer intern at Septerna, the GPCR-based biotechnology company founded by Duke Nobel laureate Dr. Robert Lefkowitz. In the fall, Julia will begin her MD/PhD training. Julia Gardner on the web Rajagopal Lab Google Scholar ResearchGate LinkedIn Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Chris Tate About this episode Dr. Chris Tate obtained his Ph.D. from the University of Bristol in 1989 and then moved to the University of Cambridge (Dept. of Biochemistry) to work on bacterial sugar transporters. After obtaining a research fellowship at Girton College (Cambridge) he moved to the LMB in 1992 to work in Richard Henderson's group on the serotonin transporter. Chris also worked on the E. coli multidrug transporter EmrE and obtained both 2D and 3D crystals as well as a 3D structure using cryo-EM. In 2005 he started working on the development of conformational thermostabilization of GPCRs, which resulted in the structure of the β1-adrenoceptor. Subsequent work has focused on understanding the molecular basis of GPCR pharmacology through structure determination of the β1-adrenoceptor and adenosine A2A receptor in multiple different conformations bound to ligands of different efficacy. In 2016 mini-G proteins were developed as a tool for the structure determination of GPCRs in the fully active state. Structures have been determined by X-ray crystallography of receptors coupled to either mini-Gs or mini-Go, and also by electron cryo-microscopy of receptors coupled to mini G protein bound to βγ subunits. Recent work includes the first structure determination of a GPCR bound to a biased agonist and coupled to arrestin and also the first structure of a Class D receptor. Join me to learn more about Chris’s work and his role in founding Heptares which was later acquired by Sosei and became Sosei Heptares . Dr. Chris Tate on the web LinkedIn ResearchGate Pubmed Google Scholar Sosei Heptares Wikipedia MRC Laboratory of Molecular Biology Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → 🔍 Running a GPCR lab? Applying for grants? Launching a nonprofit? Ep.165 of the Dr.GPCR Podcast is your finance + operations crash course—delivered by two experts who support early-stage mission-driven teams like Dr. GPCR. 🎧 Smart, practical, and full of real talk: Ep 165 with Chuck DeWeese & Joe St. Germain #gpcr #DrGPCR #ScienceStartup Published on May 15, 2025 Category Dr. GPCR Podcast 🔍 Running a GPCR lab? Applying for grants? Launching a nonprofit?Ep.165 of the Dr.GPCR Podcast is your finance + operations crash course—delivered by two experts who support early-stage mission-driven teams like Dr. GPCR. 🎧 Smart, practical, and full of real talk: Ep 165 with Chuck DeWeese & Joe St. Germain #gpcr #DrGPCR #ScienceStartup Previous Next Recent Articles

Home → Flash News → A high-resolution deep mutational scan of MC4R reveals how thousands of genetic variants impact obesity-linked signaling pathways and highlights new opportunities for precision drug discovery Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/high-resolution-deep-mutational-scanning-of-the-melanocortin-4-receptor-enables-target-characterization-for-drug-discovery #gpcr#drgpcr Published on May 5, 2025 Category GPCR Weekly News A high-resolution deep mutational scan of MC4R reveals how thousands of genetic variants impact obesity-linked signaling pathways and highlights new opportunities for precision drug discovery Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/high-resolution-deep-mutational-scanning-of-the-melanocortin-4-receptor-enables-target-characterization-for-drug-discovery #gpcr#drgpcr Previous Next Recent Articles

Home → Flash News → Check out our #SpotifyWrapped 🚀! In 2024, Dr. GPCR reached listeners worldwide, sparking conversations about GPCRs with top experts. Thank you for tuning in! 📊🎙️ ✳️Check out our top episode: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-148-with-dr-arthur-christopoulos #gpcr #drgpcr Published on January 29, 2025 Category Check out our #SpotifyWrapped 🚀! In 2024, Dr. GPCR reached listeners worldwide, sparking conversations about GPCRs with top experts. Thank you for tuning in! 📊🎙️ ✳️Check out our top episode: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-148-with-dr-arthur-christopoulos #gpcr #drgpcr Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Nicole Perry-Hauser About Nicole (Nicki) Perry-Hauser I am a postdoctoral research fellow endeavoring to build a productive, independent scientific research career in adhesion G protein-coupled receptor (aGPCR) biology. My long-term research interests involve resolving signaling pathways downstream of aGPCRs and establishing how/if these receptors’ adhesive properties influence signaling events, and in turn, whether signaling impacts synapse formation and neuronal wiring. Mutations in aGPCRs have been linked to various neuropsychiatric phenotypes, and my work will provide a basis for understanding aGPCR biology in the nervous system. Nicole (Nicki) Perry-Hauser on the web LinkedIn Research Gate Pubmed Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → Did you know that GPR20, a potential therapeutic target to treat gastrointestinal stromal tumours, performs high constitutive activity when coupling with Gi? Check out this paper to see how molecular dynamics simulation can be used to explore its constitutive activation mechanism. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/exploring-the-constitutive-activation-mechanism-of-the-class-a-orphan-gpr20 #gpcr #drgpcr Published on February 13, 2025 Category GPCR Weekly News Did you know that GPR20, a potential therapeutic target to treat gastrointestinal stromal tumours, performs high constitutive activity when coupling with Gi? Check out this paper to see how molecular dynamics simulation can be used to explore its constitutive activation mechanism. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️ https:// www.ecosystem.drgpcr.com/receptor-activation-and-signaling/exploring-the-constitutive-activation-mechanism-of-the-class-a-orphan-gpr20 #gpcr #drgpcr Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) The Scientist's Compass: From Academia to Entrepreneurship with Dr. Dmitry Veprintsev In this episode, Yamina sits down with Prof. Dmitry Veprintsev , a molecular pharmacologist at the University of Nottingham, to discuss his scientific journey, GPCR research, and the intersection of academia and entrepreneurship. Key Takeaways: From Protein Folding to GPCRs – How Dmitry transitioned from biophysics and protein folding to cannabinoid receptor research, guided by key mentors like Michel Bouvier. Why GPCRs? – The challenge and excitement of working with notoriously difficult-to-study membrane proteins. The Power of Asking the Right Question – Dmitry emphasizes that mastering a technique isn’t enough—true scientific breakthroughs come from formulating the right biological questions. Building Z7 Biotech – The unexpected journey into biotech entrepreneurship, providing GPCR profiling services to pharma and biotech companies. Interdisciplinary Research & Future Directions – Exploring combinatorial drug actions, receptor interactions, and novel profiling approaches. Networking & Career Growth – Overcoming introversion, the importance of talking to people, and how networking (or just genuine curiosity) opens doors in science. 💡 Big Takeaway? Whether in academia or industry, success comes from curiosity, persistence, and knowing your values. Tune in to hear how Dmitry navigated his career, the challenges of studying GPCRs, and why talking to others will always lead to answers! Summary made with AI About Dmitry Veprintsev Dmitry is Professor of Molecular and Cellular Pharmacology at the Centre of Membrane Proteins and Receptors (COMPARE), University of Nottingham, where he provides leadership in structural and biophysical pharmacology of G protein coupled receptors. He is author of over 100 papers, including several in Nature, Science and Cell. Dmitry studied biophysics at the Moscow State University, followed by a PhD (1998) in protein folding at the Russian Academy of Sciences and at the Ohio State University, USA. He joined the MRC Centre for Protein Engineering and later at the MRC Laboratory of Molecular Biology in Cambridge, UK as a postdoctoral fellow and later as a staff scientist, focusing on the biophysical studies of the tumour suppressor p53. In 2010 he became a group leader at the Paul Scherrer Institute and ETH Zürich in Switzerland, changing his attention to structural pharmacology of G protein-coupled receptors (GPCRs). In 2017 Dmitry became a full professor at the Centre of Membrane Proteins and Receptors, COMPARE, a joined venture between the University of Birmingham and the University of Nottingham. In 2021 he co-founded Z7 Biotech, developing and providing innovative GPCR drug screening and precision pharmacology services. Dmitry Veprintsev on the web LinkedIn Veprintsev Lab Z7 Biotech University of Nottingham Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Steven Foord About Dr. Steven Foord Steve Foord trained as a Physiologist and Pharmacologist and worked for Glaxo through to GSK from 1986 to 2008. He introduced molecular pharmacology to a wide range of the company's GPCR projects and was able to initiate some projects. These included the identification of RAMPs (solving some CGRP family issues) and the GABA B, carboxylic, and nicotinic acid receptors. He also discovered and championed a novel prostaglandin EP4 drug candidate for development. He finished his career as Head of Bioinformatics for Neuroscience and working on the GSKs novel genetics initiative. Dr. Steven Foord on the web LinkedIn Google Scholar Pubmed Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Rosie Dawaliby About Dr. Rosie Dawaliby "I’m an expert in early-stage drug discovery, targeting membrane proteins, especially GPCR. I have 10 years of experience in the development and management of R&D projects and teams in the field of pharmacology, in prestigious academic laboratories as well as in biopharmaceutical companies in Europe and the United States. I hold a Ph.D. in Life Sciences from the University of Lausanne, Switzerland, Department of Biochemistry (2005-2009), where I started working on membranes and membrane protein biochemistry by studying membrane fusion and autophagy in yeast and mammalian cells. I have developed my expertise in the field of pharmacology and biochemistry of GPCR and the crucial role of the lipidic environment on their structure and function during my post-doctoral work (2010-2015). This joint project between prof. Brian Kobilka's lab at Stanford University and the SFMB laboratory at the Université Libre de Bruxelles (ULB) resulted in the first systematic study of phospholipid's effect on GPCR conformation and function. In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases. I developed G.CLIPS biotech's innovative technology as a synthesis of the different knowledge, experiences, and know-how from the different stages of my career. Before founding G.CLIPS biotech in June 2020. And since then, my incredible adventure as CEO of this fast-growing company started and is continuing." Dr. Rosie Dawaliby on the web LinkedIn Dr. GPCR Ecosystem G.CLIPS Biotech on the web Website LinkedIn Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Josh Pottel About Dr. Josh Pottel "I lead Molecular Forecaster Inc. (MFI): a reliable, self-sustaining computational chemistry service provider, developing its own software for application in various drug discovery campaigns. I have extensive training in computer-aided drug design. I completed my PhD at McGill University in the lab of Prof. Nicolas Moitessier, and went on to a postdoc with Prof. Brian Shoichet at UCSF. While in San Francisco, I completed Startup101 - a course a offered by the entrepreneurship center. I am now combining my training as a chemist and as an entrepreneur to grow a sustainable service and software provider in drug discovery. More broadly, I hope to be a critical contributor to a growing Canadian biotech sector in both scientific research and fostering entrepreneurship." Dr. Josh Pottel on the web Molecular Forecaster LinkedIn BlueSky Google Scholar Twitter Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. J. Silvio Gutkind About this episode Have you had moments that defined your scientific tastes? For Dr. J Silvio Gutkind, a class on oncogenes and his interests for GPCRs helped shape his scientific interests. These took him from the University of Buenos Aires in Argentina to UC San Diego and through the National Institutes of Health in Bethesda, Maryland. In this episode, Silvio discusses G protein signaling in the context of cancer, immunotherapies, and combination therapies that could help improve patients’ lives. Dr. J. Silvio Gutkind on the web Dr. J Silvio Gutkind on LinkedIn Gutkind Lab – UC San Diego Moores Cancer Center Gutkind Lab publications Gutkind Lab on Pubmed Gutkind Lab on Twitter UCSD Moores Cancer Center Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

A collaboration between chemistry and biology sparked a GPCR imaging breakthrough, leading to new chemical probes for GLP-1R visualization in real tissue. Home → Flash News → A GPCR imaging breakthrough that didn’t start in a grant proposal A GPCR imaging breakthrough that didn’t start in a grant proposal Published on December 3, 2025 Category It started with a cold email. A young chemist, Dr. Johannes Broichhagen, was asked if he could synthesize a molecule “when you’re back in Munich.” That small moment pulled him into islet biology, confocal imaging, and a collaboration that would reshape how GLP-1R is visualized in real tissue. The new blog takes you behind the scenes — the London trip, the early confocal experiments, the pivot to chemical probes, and the trust-driven partnership that sparked a new era in GPCR imaging. If you care about chemical biology, receptor visualization, or building tools that actually work in complex systems, this one is worth reading. 🔗 Read the full story : https://www.ecosystem.drgpcr.com/post/how-collaboration-sparked-a-gpcr-imaging-breakthrough-in-chemical-biology Previous Next Recent Articles

Dr. Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights. Home → Flash News → How sensitive can a GPCR really be How sensitive can a GPCR really be? Published on November 9, 2025 Category Dr. GPCR Podcast Think femtomolar. That’s the scale we’re talking about. This week on the Dr. GPCR Podcast , we sit down with Michelle Halls , leader of the Spatial Organisation of Signalling lab at Monash University. Her team is redefining how we understand GPCR signaling — not just at the cell surface, but in space, time, and disease context. In this episode, you’ll learn: How GPCR pre-assembly enables femto-level signal detection. Why receptor location matters as much as receptor type. How disease can hijack signaling organization — and what that means for drug discovery. Michelle’s work bridges elegant mechanistic biology with translational impact — giving us new ways to think about receptor pharmacology, biased agonism, and therapeutic precision. 🔗 Listen here → https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling 🎓 Explore Dr. GPCR Premium → https://www.ecosystem.drgpcr.com/gpcr-university #GPCR #DrGPCR #pharmacology #drugdiscovery #receptors #biotech #signaltransduction Previous Next Recent Articles

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Unveiling Non-Canonical Functions for Gαq Signaling Pathways Date & Time Friday, November 3rd / 11:55 AM About Catalina Ribas " Dr. Catalina Ribas, is currently an Associate Professor at the University Autonomous of Madrid (UAM) and she has been Academic Secretary of Molecular Biology Department for several years. The research group led by Dr. Catalina Ribas, located in the Centro de Biología Molecular “Severo Ochoa” (UAM/CSIC) and belongs also to the Health Research Institute La Princesa, has extensive experience in the field of GPCR. Dr. Catalina Ribas made a postdoctoral stay in the laboratory of Dr. SM. Lanier in the MUSC (USA). During this period and her doctoral thesis, she has deepened the regulatory mechanisms of GPCR signaling. In her postdoctoral period, she has participated in the identification and characterization of proteins that act at the level of G proteins and which are part of a multimolecular signaling complex (AGS, de “Activators of G-protein signaling). In Spain, Dr. Ribas continued working on the regulation of GPCR. The group of Dr. Ribas has characterized the existence of a new signaling pathway with a relevant role in cardiac hypertrophy led by a new Gαq interactome. Recently, Dr. Ribas' group has described a new interaction region in a cellular protein that has turned out to be very relevant in the control of the cellular process known as autophagy. These results have been published in the journal Nature Communications (12 (1):4540, 2021) with the title "Gαq controls autophagy via modulation of the mTORC1 signaling hub". Furthermore, Dr. Ribas has also described a new protective role of G protein-coupled receptor kinase 2 (GRK2), a known regulator of Gq-GPCR signaling in HNSCC tumor progression (International Journal of Cancer, 2020). " Catalina Ribas on the web Severo Ochoa Molecular Biology Center X (Twitter) Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

Explore Terry’s Pharmacology Vault. Master irreversible kinetics, target depletion, and structured tissue penetration in real drug discovery contexts. Home → Flash News → irreversible drugs post 3 Irreversible kinetics = strategic lever in drug design. Published on October 27, 2025 Category Terry's Corner Receptor pharmacology has evolved. Irreversible interactions are no longer niche curiosities — they’re strategic levers that shape how molecules behave in vivo and whether candidates advance or stall in discovery. Inside Terry’s Corner, you’ll gain access to focused, high-impact modules built for teams who need to engineer binding kinetics, not just potency . These lessons bridge molecular pharmacology with real-world design strategy, giving discovery teams the tools to make smarter decisions earlier in the pipeline. Here’s what’s covered in this week’s lesson: Target depletion vs. replenishment dynamics — how offset rates control exposure windows, shape therapeutic durability, and influence dosing intervals. Structured tissue penetration challenges — why high-affinity molecules stall at the periphery and how to optimize kinetic profiles for deeper reach. Quantifying irreversible activity (K_inact / K_I) — turning persistent binding into measurable design parameters that guide candidate optimization. Join to learn the same principles guiding successful drug programs today. 🟢 Browse the full video vault and stay ahead of the curve: ✳️ Courses by Terry | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #DrugDiscovery #Kinetics #ReceptorPharmacology #MedicinalChemistry #PKPD #DrugDevelopment Previous Next Recent Articles

Home → Flash News → How does a superagonist activate M2 muscarinic receptors? New simulations reveal the conformational changes from inactive to active states to highlighting how ligand dynamics drive GPCR activation! Catch the full story in the Ecosystem! https://www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function/visualizing-agonist-induced-m2-receptor-activation-regulated-by-aromatic-ring-dynamics #GPCR #drGPCR #M2R #drugdiscovery #moleculardynamics Published on March 31, 2025 Category GPCR Weekly News How does a superagonist activate M2 muscarinic receptors? New simulations reveal the conformational changes from inactive to active states to highlighting how ligand dynamics drive GPCR activation! Catch the full story in the Ecosystem! https://www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function/visualizing-agonist-induced-m2-receptor-activation-regulated-by-aromatic-ring-dynamics #GPCR #drGPCR #M2R #drugdiscovery #moleculardynamics Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Dr. Peter Robert Banks About Dr. Peter Robert Banks Peter Banks is currently the Scientific Director at BioTek Instruments , now a part of Agilent . His responsibilities include the management of the company’s applications team and providing scientific guidance to the senior management team on new technology and emerging trends impacting life sciences. Before joining BioTek in 2008, Banks was employed by PerkinElmer for a decade. These roles included management of PerkinElmer’s BioPharma R&D program and Chair of the company’s Scientific Advisory Board. Prior to experiences at PerkinElmer and BioTek, Banks was an Assistant Professor in Analytical Chemistry at Concordia University, Montreal, Canada from 1994 to 1998. Dr. Peter Robert Banks on the web LinkedIn Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → A complete profile = a complete YOU. Highlight your publications, skills, and interests to connect with the right people! ✳️Go to https://www.ecosystem.drgpcr.com/account/my-account and update your profile on the Dr.GPCR. #gpcr #drgpcr Published on February 5, 2025 Category Dr. GPCR Profiles A complete profile = a complete YOU. Highlight your publications, skills, and interests to connect with the right people! ✳️Go to https://www.ecosystem.drgpcr.com/account/my-account and update your profile on the Dr.GPCR. #gpcr #drgpcr Previous Next Recent Articles

Home → Flash News → In Ep.163 of the Dr. GPCR Podcast, Dr. Dmitry Veprintsev discusses the importance of asking the right GPCR question. It’s not just about learning the techniques; it’s about curiosity! 👀 Do you remember any question that changed your perspective completely? 💡 ✳️Visit https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-163-with-dr.-dmitry- #DrGPCR #GPCRPodcast #Pharmacology #DrugDiscovery #GPCRScience Published on April 8, 2025 Category Dr. GPCR Podcast In Ep.163 of the Dr. GPCR Podcast, Dr. Dmitry Veprintsev discusses the importance of asking the right GPCR question. It’s not just about learning the techniques; it’s about curiosity! 👀 Do you remember any question that changed your perspective completely? 💡 ✳️Visit https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-163-with-dr.-dmitry- #DrGPCR #GPCRPodcast #Pharmacology #DrugDiscovery #GPCRScience Previous Next Recent Articles

Discover how enzyme inhibition can enhance drug discovery strategies. Explore inhibition modes, CYP450 allostery, and insights from Dr. Eric Trinquet in this week's news. Home → Flash News → Weekly News October 16 Published on October 16, 2025 Category GPCR Weekly News Enzymes decide which molecules get a real shot at efficacy. This week’s Weekly News is your practical guide to building enzyme inhibition into discovery—not as a checkbox, but as a strategy. We unpack inhibition modes (competitive, noncompetitive, mixed, uncompetitive), the messy truth of CYP450 allostery and DDIs, and why allosteric control can protect potency in substrate-rich environments. Plus: a mindset masterclass from Dr. Eric Trinquet —how structured play turns into assays and why serendipity belongs in your build process. And a tertiary read on ciliary micro-domains linking OPN3/MCR signaling to appetite and skin biology. Read the full Weekly News ➤ https://lnkd.in/eWkAphen If this helped, pass it along to a colleague who needs the signal. #DrGPCR #GPCR Previous Next Recent Articles

Home → Flash News → What’s one key piece of advice from Ian Chronis in Ep.164 of the Dr.GPCR Podcast?Listen to other scientists’ research—it’s a great way to stay motivated and inspired 🚀 Don’t miss this insightful conversation on GPCRs, pharmacology, and scientific discovery! ✅ https://buff.ly/FTB69y9 #GPCR #DrGPCR #SciencePodcast #Pharmacology #CancerResearch Published on April 24, 2025 Category Dr. GPCR Podcast What’s one key piece of advice from Ian Chronis in Ep.164 of the Dr.GPCR Podcast?Listen to other scientists’ research—it’s a great way to stay motivated and inspired 🚀 Don’t miss this insightful conversation on GPCRs, pharmacology, and scientific discovery! ✅ https://buff.ly/FTB69y9 #GPCR #DrGPCR #SciencePodcast #Pharmacology #CancerResearch Previous Next Recent Articles

<< Back to podcast list Strategic Partner(s) Dr. Raul Gainetdinov About Dr. Raul Gainetdinov Raul R. Gainetdinov is the Institute of Translational Biomedicine Director at Saint Petersburg State University (SPBU), Russia. Before SPBU, Raul R. Gainetdinov was a Senior Researcher in the Department of Neuroscience and Brain Technologies at the Italian Institute of Technology in Genova, Italy (2008-2016) and an Associate Research Professor in the Department of Cell Biology at Duke University in North Carolina, USA (1996-2008). From 2013-2018, he was also a Professor at the Skolkovo Institute of Science and Technology (Skoltech), Moscow. Before joining the Department of Cell Biology in 1996 as a postdoc and becoming faculty at Duke in 2000, he researched at the Institute of Pharmacology Russian Academy of Medical Sciences in Moscow (1988-1996). He received a Ph.D. in pharmacology in 1992 from the Russian Academy of Medical Sciences and an M.D. in 1988 from the Second Moscow Medical Institute, Moscow, Russia. Since 2013, he has been elected Chair of the subcommittee for the Dopamine receptors of the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR). As of August 2022, he has over 270 publications in scientific journals (including Science, Nature, Cell, and PNAS) and co-authored 13 patents. His papers were cited over 28,000 times (H-index – 81, ISI Web of Science). In 2018-2020, Raul R. Gainetdinov was included in the Web of Science (WOS) Highly Cited Researchers (HCR) list, representing the top 0.1% of scientists worldwide. Dr. Raul Gainetdinov on the web Saint-Petersburg State University Wikipedia Google Scholar Researchgate Google Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) Dr. Masha Niv About this episode Dr. Niv is currently an associate professor and vice dean for research at the Hebrew University of Jerusalem. The Niv lab is also part of the Global Consortium for Chemosensory Research. Masha earned her Bachelor’s degree in chemistry, followed by a direct Ph.D. at the Institute of Chemistry, at The Hebrew University of Jerusalem in Israel. Dr. Niv trained as a postdoctoral fellow at Weill Cornell Medical College. Her work focuses on both sweet and bitter taste receptor GPCRs and her lab established the BitterDB . Dr. Masha Niv on the web Niv Lab LinkedIn Twitter Pubmed Google Scholar Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Strategic Partner(s) GPCR location matters with Dr. Gabriele Kockelkoren About Gabriele Kockelkoren I have a strong background in both physics and molecular biology and, accordingly, I strive in interdisciplinary environments. After completing a cum laude BSc. and MSc. in Nanobiology at the Technical University of Delft in The Netherlands, I pursued a PhD at the University of Copenhagen under the supervision of Prof. Dimitrios Stamou. In my PhD, I studied the nanoscale spatial organization of G protein-coupled receptors (GPCRs) at the plasma membrane of living cells. Importantly, my work revealed heterogeneous spatial patterns of receptor density and activation, that are modulated in a drug-dependent manner. These findings identify nanoscale GPCR spatial organization as an integral element of their activity and signaling. Currently, I am a Postdoctoral Fellow in the lab of Prof. Alice Ting developing programmable receptors for molecular sensing and controlling cellular behaviour. Gabriele Kockelkoren on the web Stanford University X LinkedIn Google Scholar ORCID ResearchGate Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>